Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
52 hedge funds and large institutions have $298M invested in Translate Bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 5 reducing their positions, and 6 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 5
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
50% more capital invested
Capital invested by funds: $200M → $298M (+$98.9M)
11% more funds holding
Funds holding: 47 → 52 (+5)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$10.4M |
| 2 |
BlackRock
New York
|
+$7.54M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.4M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$1.36M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.07M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.32M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$1.72M |
| 4 |
Two Sigma Investments
New York
|
-$118K |
| 5 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$113K |
TBIO Hedge Fund Activity: Q1 2019 in Review
52 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q1 2019, worth a combined $298M — up 50% from $200M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new TBIO positions and 6 closed out — a net gain of 5 holders — while 25 added to existing stakes and 5 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $10.4M. The largest seller was Farallon Capital Management, cutting an estimated $3.07M.
- 52 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q1 2019, up from 47 in Q4 2018.
- Funds reported $298M of Translate Bio, Inc. Common Stock stock for Q1 2019, up 50% quarter-over-quarter.
- 11 funds opened new Translate Bio, Inc. Common Stock positions in Q1 2019 and 6 closed out, a net change of +5 holders.
- The largest Translate Bio, Inc. Common Stock buyer in Q1 2019 was RTW Investments, an estimated $10.4M added.
- The largest Translate Bio, Inc. Common Stock seller in Q1 2019 was Farallon Capital Management, an estimated $3.07M sold.
Based on aggregated 13F filings for Q1 2019.